Skip to main content
. Author manuscript; available in PMC: 2021 Dec 10.
Published in final edited form as: Gynecol Oncol. 2021 Jun 6;162(2):249–255. doi: 10.1016/j.ygyno.2021.05.038

Table 3.

Results of the Markov cohort model for patients with high microsatellite instability endometrial cancer.

N = 1500 each cohort Pembrolizumab/Lenvatinib Carboplatin/Paclitaxel
Respond (n) 380 488
Progress (n) 692 187
Death (n) 427 826
Cost ($) 362,335 48,848
Difference in costs 313,487
Effectiveness (QALY) 1.79 1.68
Incremental effectiveness (QALY) 0.11
ICER ($) 2,849,882